Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs CLARINEX-D 12 HOUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Relief of symptoms associated with seasonal allergic rhinitis,Relief of symptoms associated with perennial allergic rhinitis,Relief of nasal congestion and sinus pressure
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Desloratadine: primarily metabolized by CYP3A4 and CYP2D6 to active metabolite 3-hydroxydesloratadine. Pseudoephedrine: partially metabolized in liver by N-demethylation via CYP450 enzymes; largely excreted unchanged in urine.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
38-45%, primarily bound to albumin.
Desloratadine: 83-87% (mainly albumin); pseudoephedrine: negligible binding.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Desloratadine: 49 L (approx. 0.7 L/kg), extensive tissue distribution; pseudoephedrine: 2.6-3.5 L/kg.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Desloratadine: 100% (oral); pseudoephedrine: ~100% (oral).
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
Contraindicated in patients with GFR < 60 m L/min due to pseudoephedrine component.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific Child-Pugh based adjustments for desloratadine; pseudoephedrine may require caution in severe hepatic impairment.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Not recommended for use in pediatric patients under 12 years of age.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Use with caution; initiate at lower doses due to increased sensitivity to pseudoephedrine and risk of anticholinergic effects.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
None.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Cardiovascular effects: Use with caution in patients with hypertension, arrhythmias, or ischemic heart disease.,CNS stimulation: May cause insomnia, dizziness, or nervousness.,Urinary retention: Use with caution in patients with prostatic hypertrophy or bladder neck obstruction.,Renal impairment: Reduce dose or avoid in severe renal impairment.,Hepatic impairment: Caution in severe hepatic disease.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Concurrent use with MAO inhibitors or within 14 days of stopping MAOI,Narrow-angle glaucoma,Urinary retention,Breastfeeding
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented foods) as pseudoephedrine may potentiate pressor effects. Taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice; it may increase desloratadine levels. Limit caffeine intake as it can add to CNS stimulation.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogenicity at doses 210 times human exposure, but potential for adverse effects is unknown. Pseudoephedrine: Case reports suggest possible association with gastroschisis at first-trimester exposure; vasoconstriction may reduce uteroplacental blood flow, especially in third trimester. Avoid in first trimester if possible; use only if benefit outweighs risk.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Desloratadine: Excreted into breast milk; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. Pseudoephedrine: Excreted into breast milk; estimated infant dose ~2-7% of maternal dose; may cause irritability, sleep disturbance. M/P ratio: not reported for desloratadine; pseudoephedrine M/P ~3.0. Manufacturer recommends caution due to pseudoephedrine's effects.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No specific dose adjustments required for desloratadine; pregnancy may increase volume of distribution but no clinical studies. Pseudoephedrine: Pregnancy may reduce clearance; no formal dose adjustment but use lowest effective dose and shortest duration. Monitor for hypertension.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
CLARINEX-D 12 HOUR (desloratadine/pseudoephedrine) combines a non-sedating antihistamine with a sympathomimetic decongestant. Pseudoephedrine can cause hypertension, tachycardia, and urinary retention; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Desloratadine is the active metabolite of loratadine; it is less sedating than first-generation antihistamines. The 12-hour formulation requires twice-daily dosing. Monitor for CNS stimulation and insomnia, especially in elderly or pediatric patients.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take one tablet every 12 hours with a full glass of water; do not crush or chew.,Do not exceed 2 tablets in 24 hours.,Avoid alcohol and other CNS depressants while taking this medication.,May cause dizziness or drowsiness; avoid driving until you know how the medication affects you.,Notify your doctor if you have high blood pressure, heart disease, thyroid problems, or difficulty urinating.,Discontinue use and seek medical attention if you experience chest pain, rapid heartbeat, or difficulty breathing.,Do not take with other decongestants or antihistamines without consulting a healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs CLARINEX-D 12 HOUR, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. CLARINEX-D 12 HOUR is a Antihistamine/Decongestant Combination that works by Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and CLARINEX-D 12 HOUR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of CLARINEX-D 12 HOUR is: 1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and CLARINEX-D 12 HOUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. CLARINEX-D 12 HOUR is classified as Category C. Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogen. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.